Charles River (CRL) and Toxys announced a collaboration that offers Charles River’s clients access to ReproTracker, a human stem cell-based in vitro assay that rapidly and reliably identifies developmental toxicity hazards of new drugs and chemicals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River upgraded to Outperform from Market Perform at William Blair
- Charles River price target raised to $200 from $190 at Evercore ISI
- Nike upgraded, RH downgraded: Wall Street’s top analyst calls
- Charles River upgraded to Overweight from Equal Weight at Barclays
- Charles River Labs: Navigating Leadership Changes and Market Challenges with a Hold Rating